Viewray Inc (NASDAQ:VRAY) was down 3.1% on Friday . The stock traded as low as $6.78 and last traded at $6.65. Approximately 882,060 shares changed hands during trading, an increase of 32% from the average daily volume of 665,805 shares. The stock had previously closed at $6.86.
Several equities research analysts recently weighed in on VRAY shares. ValuEngine lowered Viewray from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. BidaskClub lowered Viewray from a “buy” rating to a “hold” rating in a research report on Saturday, December 9th. Cantor Fitzgerald restated an “overweight” rating on shares of Viewray in a research report on Friday, January 5th. Mizuho restated a “buy” rating and set a $12.00 price target on shares of Viewray in a research report on Tuesday, January 9th. Finally, B. Riley started coverage on Viewray in a research report on Thursday, February 8th. They set a “buy” rating and a $13.50 price target on the stock. Two equities research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. Viewray presently has an average rating of “Buy” and a consensus price target of $11.58.
The company has a debt-to-equity ratio of 22.47, a current ratio of 2.18 and a quick ratio of 1.84. The company has a market cap of $519.43, a price-to-earnings ratio of -5.28 and a beta of 0.21.
Viewray (NASDAQ:VRAY) last released its earnings results on Monday, March 12th. The company reported ($0.38) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.13). The business had revenue of $19.90 million during the quarter, compared to analyst estimates of $21.23 million. The business’s quarterly revenue was up 23.6% compared to the same quarter last year. equities research analysts forecast that Viewray Inc will post -0.71 EPS for the current fiscal year.
In other Viewray news, insider James F. Dempsey sold 75,243 shares of the business’s stock in a transaction on Wednesday, March 14th. The stock was sold at an average price of $7.57, for a total value of $569,589.51. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 62.81% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the business. Park West Asset Management LLC purchased a new position in shares of Viewray in the fourth quarter worth $24,217,000. BlackRock Inc. raised its stake in shares of Viewray by 19.8% in the fourth quarter. BlackRock Inc. now owns 1,853,268 shares of the company’s stock worth $17,160,000 after purchasing an additional 306,395 shares during the last quarter. RTW Investments LP raised its stake in shares of Viewray by 32.1% in the fourth quarter. RTW Investments LP now owns 1,348,210 shares of the company’s stock worth $12,484,000 after purchasing an additional 327,748 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Viewray by 67.0% in the second quarter. Vanguard Group Inc. now owns 1,026,880 shares of the company’s stock worth $6,644,000 after purchasing an additional 411,866 shares during the last quarter. Finally, Sectoral Asset Management Inc purchased a new position in shares of Viewray in the fourth quarter worth $8,772,000. 80.80% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This story was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://ledgergazette.com/2018/03/23/viewray-vray-trading-down-3-1.html.
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.